Welcome
Published on
December 18, 2023
Welcome
Welcome to MRX Medical News. MRX Medical News aims to be a trusted source for important MRX updates, industry insights and clinical/scientific information on the use of cannabinoids in healthcare.
MRX Medical is committed to cannabinoid pharmaceutical development and the treatment of complex, chronic inflammatory pain conditions. We are applying the rigorous standards of traditional pharmaceutical drug development to create quality medicines that target hard‑to‑treat conditions and are suitable for clinical trials and use in healthcare settings.
In practice, this means that we concentrate on three core areas:
1. Developing Quality Cannabinoid Medicines in the UK that meet medical and pharmaceutical standards:
Our commitment to quality begins with the development of our medicines, manufactured in the UK, adhering to EU GMP standards. Our medicines meet the requirements and principles for investigational medicinal products and are suitable for use in clinical trials. We are already partnering with world-leading researchers to undertake clinical studies, including an initial two Phase II RCTs being conducted by The University of Edinburgh using one of our patent pending cannabidiol oils.
2. Collaborating with Leading Academic Institutions and Researchers:
We collaborate with world-renowned universities and esteemed researchers to conduct robust clinical trials targeting the treatment of complex, chronic inflammatory pain conditions. These partnerships ensure the scientific rigor and credibility of our research efforts.
3. Bringing Patented and Licensed Cannabinoid Medicines to Patients:
Our goal is to commercialise patented and licensed cannabinoid medicines, making them accessible to patients through the National Health Service (NHS) in the UK.
Our Mission
So, why are we so passionate about this field of medicine? The answer is straightforward: there are approximately 28 million individuals in the UK alone grappling with chronic pain, and we see an opportunity to improve their quality of life. Many of these individuals encounter difficulties accessing effective treatments or contend with adverse side effects from existing options. In cases such as chemotherapy-induced peripheral neuropathy (CIPN), viable treatments are nearly non-existent.
Chronic pain imposes a substantial financial burden on the NHS and the broader economy. Mounting pre-clinical, clinical, and real-world evidence suggests that cannabinoids hold significant potential for treating some of these conditions in a cost-effective manner with fewer side effects.
To bring cannabinoid medicines to market and achieve meaningful uptake, clinical research is required to establish their efficacy. MRX is meeting this need by placing a strong emphasis on providing robust clinical evidence, with CBD as the primary active pharmaceutical ingredient. Our focus is initially on conditions such as endometriosis, neuropathic pain, fibromyalgia, and epilepsy.
We are excited to have already forged a partnership with the University of Edinburgh that will deliver two Phase II placebo-based randomised controlled trials (RCTs), financed with non-dilutive grant funding totalling £1.55 million.
One of these trials will utilise our patent pending MRX1 cannabidiol oil to address the pelvic pain associated with endometriosis. Endometriosis is a debilitating condition that has been hugely underfunded in terms of research, despite currently affecting over 1.5 million women in the UK.
The other trial will use MRX1 in a double-blind, placebo-controlled crossover RCT to target CIPN. CIPN is a nerve-related condition characterised by tingling, numbness, and extremity pain. CIPN not only affects patients' physical well-being, but also profoundly impacts their overall quality of life and daily activities. Alarmingly, approximately 160,000 new CIPN cases emerge in the UK each year.
MRX continues to seek out additional clinical trials with a strong focus on conditions that are poorly treated, have large addressable markets and display promising pre-clinical or clinical evidence.
Thank you for your interest in what we do and our ambition to improve the treatment of complex, chronic inflammatory pain conditions. Stay tuned for more updates and insights from MRX Medical News.
If you are interested in learning more, joining our mailing list or would like to talk to us, please don't hesitate to reach out to us at info@mrxmedical.com.
MRX Medical is an Ananda Developments plc company. Ananda is a company quoted on the Aquis Stock Exchange (AQSE: ANA) Growth Market. To find out more visit the Ananda Investor Hub or follow us on social media:
